Chief Financial Officer
Kevin Sarney’s 20-year career spans experience in both public and private biotech companies, driving long-range financial plans in concert with strategic planning. He has played a key role in helping biotech companies raise capital, from confidential follow-on offerings for public companies to private equity rounds, venture debt deals and private family offices. Prior to joining Goodcell, he served as Vice President of Finance and Administration at EIP Pharma, and previously served in senior leadership roles including Interim President at Enumeral Biomedical (OTC), VP Finance at Archemix and Nitromed (NASDAQ). Mr. Sarney started his finance career at PricewaterhouseCoopers. Mr. Sarney is a licensed CPA in Massachusetts and an MBA from Boston University.